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p63 is a transcription factor structurally related to the p53 tumor suppressor. The C-terminal region differs
from p53’s in that it contains a sterile alpha motif (SAM) domain and is subject to multiple alternative
splicings. The N-terminal region is present in the transactivation (TA) and N configurations, with the latter
lacking the transcriptional activation domain 1. Single amino acid substitutions and frameshift mutations of
p63 cause the human ankyloblepharon ectodermal dysplasia clefting (AEC) or ectrodactyly ectodermal dys-
plasia and facial clefting (EEC) syndromes. We have systematically compared the activities of the wild-type p63
isoforms and of the natural mutants in activation and repression assays on three promoters modulated by p53.
We found that p63 proteins with an altered SAM domain or no SAM domain—the  isoforms, the EEC
frameshift mutant, and the missense AEC mutations—all showed a distinctly higher level of activation of the
MDM2 promoter and decreased repression on the HSP70 promoter. Fusion of SAM to the GAL4 DNA-binding
domain repressed a heterologous promoter. A second activation domain, TA2, corresponding to exons 11 to 12,
was uncovered by comparing the activation of N isoforms on natural promoters and in GAL4 fusion systems.
In colony formation assays, the AEC mutants, but not the EEC frameshift, were consistently less efficient in
suppressing growth, in both the TA version and the N version, with respect to their p63 counterparts. These
data highlight the modularity of p63, identifying the SAM domain as a dominant transcriptional repression
module and indicating that the AEC and EEC frameshift mutants are characterized by a subversion of the p63
transcriptional potential.
p53 is a sequence-specific transcription factor that plays a
critical role in activating the expression of genes involved in
cell cycle arrest and apoptosis. Under conditions of genotoxic
stress, p53 stabilization leads to transcriptional activation and
repression of different sets of genes (7). The MDM2, p21, and
GADD45 genes are among those that are activated by p53 by
direct binding to specific sites in their regulatory regions (32).
Mutations in the p53 tumor suppressor gene are the most
frequent somatic alterations found in human cancers, and hot
spots of mutations are found within the DNA-binding subdo-
main (34, 47). Many genes are down-regulated at the transcrip-
tional level by p53 with mechanisms that are less clearly de-
fined, possibly involving direct interactions with components of
the basal transcriptional apparatus (15, 22). More recently, two
genes were uncovered, referred to as the p63 and p73 genes,
encoding proteins that share significant amino acid identity
with p53 in the transactivation, DNA-binding, and oligomer-
ization domains (19, 20, 28, 37, 49). p63 and p73 are more
similar to each other than to p53, and both can activate p53-
responsive promoters (18, 26, 31, 48). An extended C-terminal
coding region, not found in p53, is present in p63 and p73 and
undergoes complex alternative splicing (21). Within this C-
terminal extension, there is a sterile alpha motif (SAM) that is
found in proteins that regulate mammalian development and is
thought to be involved in protein-protein interactions (4, 44).
In contrast to p53, p73 and p63 are rarely mutated in human
cancers (34). Another notable difference is that p63 and p73
are present as two isoforms with respect to their N termini,
with widely divergent biological properties: the transactivating
(TA) isoforms, which resemble p53, are generated by the use
of an upstream promoter; the N isoforms, produced from an
intronic promoter, contain the same DNA-binding and oli-
gomerization domains as the TA but lack the transactivation
domain (see Fig. 1). Both the TA and N isoforms have three
possible carboxyl termini, termed , , and . The  and 
isoforms lack the SAM domain.
Inactivations of genes for p53-like proteins in mice have very
different outcomes, implying that they play distinct roles in
vivo. In fact, even though p53 modulates critical cellular pro-
cesses and is ubiquitously expressed, p53 knockout mice are
developmentally normal and show increased susceptibility to
spontaneous tumorigenesis (13). Mice deficient for p73 exhibit
profound defects, including hippocampal dysgenesis, hydro-
cephalus, chronic infections, and inflammations, as well as
abnormalities in pheromone sensory pathways (50). Mice lack-
ing p63 are born alive but die soon after birth, with several
developmental defects, particularly in limb formation and in
the skin compartment (35, 51). Important clues as to the phys-
iological role of p63 came from the analysis of the molecular
defects of patients with distinct autosomal dominant syn-
dromes, caused by alteration of the p63 gene. (i) In ectrodac-
tyly, ectodermal dysplasia and cleft lip/palate (EEC) syndrome,
the phenotypes are similar to some of the features detected in
p63-deficient mice (8). All but one of the almost 50 p63 mu-
* Corresponding author. Mailing address: Dipartimento di Genetica
e Biologia dei Microrganismi, Via Celoria 26, 20133 Milano, Italy.
Phone: 02-5031-5000. Fax: 02-5031-5044. E-mail: luisa.guerrini@unimi
.it.
† Luisa dedicates this work to the memory of Giusi.
8659
tations so far identified in EEC patients create amino acid
substitutions that are predicted to abolish the DNA-binding
capacity of p63. The remaining mutation introduces a frame-
shift within exon 13 of the p63 gene that affects p63 but not
the p63 or  isotype (46). (ii) Approximately 10% of the
patients with isolated split hand-split foot malformation
(SHFM) have p63 mutations, these being either amino acid
substitutions in the DNA-binding domain or stop mutations at
the C-terminal end of p63 (17, 46). (iii) For the Hay-Wells
syndrome, also known as ankyloblepharon-ectodermal dyspla-
sia-clefting (AEC), whose phenotype is similar to but clearly
distinct from that of the EEC patients, all mutations identified
so far are single amino acid substitutions encoded within exon
13 of the p63 gene (33).
A number of studies have so far addressed the activation and
growth suppression features of some of p63 isoforms (48).
However, a comprehensive comparison of all known p63 iso-
forms on a natural rather than artificial construct is lacking.
Thus, to better comprehend the biological complexity of p63,
we undertook a systematic analysis of the transcriptional and
growth-regulating activities of six splicing variants of p63
(TAp63, -, and - and Np63, -, and -), of the exon 13
frameshift mutation isolated from an EEC patient, and of four
missense mutations causing the AEC syndrome.
MATERIALS AND METHODS
Cell culture and transfections. The Saos-2 cell line was maintained in RPMI
1640 medium supplemented with 10% fetal calf serum. For transfection, 80,000
cells were seeded into 24-well multiplates and on the following day were trans-
fected with Lipofectamine 2000 (Gibco) under the conditions suggested by the
manufacturer. The total amount of transfected DNA (1 g) was kept constant
using empty vector DNA when necessary. Thirty-six hours later, cells were
collected for chloramphenicol acetyltransferase (CAT) assays (16). For RNA
extraction, 800,000 Saos-2 cells were seeded into 60-mm-diameter dishes and, the
day after, transfected with Lipofectamine 2000 with 10 g of DNA (Gibco).
RNA preparation and analysis. Total RNAs were extracted from Saos-2 cells
by the Trizol reagent (Gibco) according to the instructions of the manufacturer.
Fifteen micrograms of each sample was loaded on a 1% formaldehyde-contain-
ing agarose gel and transferred to a nitrocellulose membrane. The following
fragments were used as probes: a 1.9-kb EcoRI fragment from the human
MDM2 gene (5) and the rat glyceraldehyde-3-phosphate dehydrogenase frag-
ment, used for normalization of RNA loading (40). Fragments were labeled with
[-32P]dCTP by the Random Primed DNA labeling kit (Boehringer).
Colony-forming efficiency assay. Saos-2 cells were transfected with p63-con-
taining plasmids, all carrying a neo-resistance gene. After 2 weeks of selection,
the G418-resistant colonies were fixed with methanol-acetic acid (2:10 [vol/vol])
and visualized by staining with 2% (wt/vol) crystal violet for easy visualization.
Plasmids. The p21/WAFCAT contains the 2.4-kb fragment from the p21/WAF
promoter (6). The Bp100 CAT reporter contains two copies of the p53RE motif
derived from the MDM2 intronic promoter (5). The Hsp70 CAT (23) and all p63
isoforms (wild type [wt] and mutants) were described previously (8, 33). The
reporter GAL4 vectors, G5XN-CAT and G5-PB11CAT, were provided by B.
Majello (29, 30).
GAL4 fusion proteins. For construction of GAL4 fusion proteins, different
oligonucleotide pairs were synthesized in order to specifically amplify exons 11,
12, and 14 from the wt TA p63 cDNA and exon 13 from wt and AEC-mutated
TA p63 cDNAs. The sequences of the oligonucleotides were as follows: exon
11, 11 Forward (GGGGATCGATTCAGACCTCAATACAG 11) and 11 Re-
verse (CCCCCTCGAGTCAAATGTTGGCTCCCAT); exon 12, 12 Forward
(CCCCATCGATTCCCATGATGGGCACC) and 12 Reverse (CCCCCTCGA
GCTAGACAATGCTGCAATC); exon 13, 13 Forward (GGGGATCGATTAG
TTTCTTAGCGAGG) and 13 Reverse (CCCCCTCGAGTCAATCCATGGAG
TAATG); exon 14, 14 Forward (GGGGATCGATTGATCTGGCAAGTCTG)
and 14 Reverse (CCCCCTCGAGTCACTCCCCCTCCTCTTT).
All oligonucleotides contained adequate restriction sites (underlined) to allow
further cloning steps. The amplification products were purified after digestion
with restriction enzymes and ligated into the pGAL4poly plasmid in frame with
the GAL4 DNA-binding domain (27). All clones were authenticated by DNA
sequencing.
Western immunoblot analysis. Thirty-six hours after transfection, cells were
lysed in loading buffer (2% sodium dodecyl sulfate, 30% glycerol, 300 mM
-mercaptoethanol, 100 mM Tris-HCl [pH 6.8]), and different volumes of total
extracts were separated on SDS–8% polyacrylamide gels and transferred to a
nitrocellulose membrane (Schleicher & Schuell). The blots were incubated with
the following antibodies: p53 (FL 393, no. sc6243) c-myc (A14, no. sc789), and
GAL4 (RK5C1, no. sc510) (Santa Cruz Biotechnology) and developed according
to the manufacturer’s instructions (Super Signal; Pierce).
RESULTS
Activation and inhibition of promoters by p63 isoforms. p63
is present in multiple isoforms, resulting in part from differ-
ential splicing and in part from the use of two promoters that
generate variations at the N-terminal end of the protein. Fig-
ure 1 shows a schematic representation of p63 complexity, as
well as the positions of the mutations identified in EEC and
AEC patients that were used in this study. Bona fide natural
p63 gene targets have not been identified so far. To test the
transcriptional activities of the different p63 isoforms, we used
two target promoters that are activated (MDM2 and p21) and
one promoter that is repressed (Hsp70) by p53. The Bp100-
CAT and p21/WAFCAT plasmids contain the intronic MDM2
promoter and the upstream control sequences and promoter of
p21, respectively, both harboring two DNA binding sites for
p53 (5). The Hsp70-CAT plasmid contains a promoter with no
known p53 binding sites that is efficiently down-regulated by
p53 (1). In these experiments, we used the human osteosar-
coma cell line Saos-2, which expresses very low levels of p73
and no p53 or p63 (6).
Initially, we verified the expression levels of the transfected
p63 isoforms. Figure 2A shows that all proteins were expressed
from the pcDNA vectors and their abundance varies to some
extent, with the  isoforms being the more abundant and the 
being the less abundant, in agreement with published results
(5); for this reason, different amounts of total cell lysates were
used: 25 l for TAp63 and TAp63 (Fig. 2A, lanes 2 and 6)
and 10 l for other p63 isoforms and p53. To take on these
differences, which could possibly alter transactivation poten-
tials, we systematically transfected different doses of plasmids
in the subsequent experiments. Results in Fig. 2B show the
transcriptional activities of dose responses of all p63 isoforms
on the p21 promoter: as expected, p53, as well as TAp63
and TAp63, activate transcription, albeit modestly, where-
as Np63 does not. Ap63 and, surprisingly, Np63 and
Np63 also activate p21 over a wide range of transfected
DNA. A different activation profile emerges from the anal-
ysis of the MDM2 reporter (Fig. 2C). Both the TAp63 and
Np63 isoforms were inefficient as transcriptional activators.
The TAp63 and Np63 isoforms activated transcription
modestly, fourfold on average (Fig. 2C). On the other hand,
the TAp63 and Np63 isoforms activated transcription very
efficiently, 10- to 15-fold, even at low levels of transfected
plasmids, with TAp63 being a stronger activator than p53.
This is remarkable, since the protein levels of the  isoforms
are consistently lower by a factor of three than those of the 
isoforms (Fig. 2A); thus, we are possibly underestimating the
TA and Np63 activation potential. Taken together, these
results are surprising, since (i) the robust activation obtained
on the MDM2 promoter with Np63 is effective despite the
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lack of the canonical TA activation domain, suggesting that an
additional transcriptional activation function(s) is contained
within p63, and (ii) the lack of activation of the TAp63 iso-
form is most likely due to sequences at the C-terminal end,
possibly suggesting that a repressive domain is present in exons
13 to 14, which are absent in the  isoform.
Several promoters were shown to be inhibited by p53 (15).
Repression assays were performed with p63 and  isoforms
but not with p63 (36). We wished to verify whether p63
isoforms have repression capacity by cotransfecting increasing
amounts of p63 plasmids with the Hsp70 promoter, a p53
target which possesses a high level of intrinsic activity even
without activation by heat shock. Indeed, promoter activity is
very efficiently repressed by p53 (10- to 15-fold; see Fig. 2D), a
result entirely consistent with previous reports (1). TAp63
and TAp63 potently inhibited transcription, whereas the cor-
responding N isoforms showed a clear reduction of the inhi-
bition capacity. On the other hand, both the TA and Np63
isoforms modestly inhibited Hsp70 promoter function. These
data suggest that two domains influence the repressing activity:
the TA domain, whose presence in the  and  isoforms guar-
antees stronger repression, and the C terminus of the protein,
the absence of which decreases repression.
No correlation has been shown so far between transient
coexpression with transfected p63 isoforms and the actual
modulation of endogenous genes. For this reason, we felt it
was important to validate the results obtained with the MDM2-
CAT reporter constructs by checking the expression of the
endogenous MDM2 gene upon cotransfection of the different
p63 isoforms described above. Thirty-six hours after the addi-
tion of p63 cDNAs, total RNA was extracted and used for
Northern blot analysis. As shown in Fig. 3, we observed a
fivefold increase with p53 and an even higher induction with
the TAp63 and TAp63 isoforms (Fig. 3A, compare lane 1
with lanes 2, 5, and 7). The TA and N p63 isoforms were
completely ineffective (Fig. 3A, lanes 3 and 4), while the N
FIG. 1. Schematic representation of p63 structure. Intron-exon structure of the p53 and p63 genes, showing the p63 transcriptional start sites
and the alternative splicing at the 3 end that gives rise to the , , and  isoforms, is shown. The change in the reading frame within exons 14
and 15 occurring in the  and  isoforms is indicated. The positions of the EEC and AEC SAM domain mutations are indicated. All mutations
fall within exon 13 and are predicted to affect only the  isoforms.
VOL. 22, 2002 COMPLEX TRANSCRIPTIONAL EFFECTS OF p63 ISOFORMS 8661
and N isoforms were very modestly active (Fig. 3A, lanes 6
and 8). These results are in line with those previously reported
for p53 (52) and largely confirmatory of the data obtained with
the reporter assays, with the exception of Np63, which is
much more efficient in the latter experimental setup.
Dissection of C-terminal repression and activation subdo-
mains. To dissect the function(s) of the p63 C-terminal region,
we used the GAL4 recruitment assay with Saos-2 cells. We
generated constructs containing exon 11, 12, 13, or 14 fused to
the yeast GAL4 DNA-binding domain. The activities of the
resulting constructs, termed hereafter G4-63-11, G4-63-12,
G4-63-13, and G4-63-14, were checked with two reporter plas-
mids: the first, the G5XN construct, which contains five
GAL4 binding sites fused to the human myc promoter se-
quences spanning from 	93 to 54 of the P2 transcription
start site, has low intrinsic activity and was used to study acti-
vation (30). The second one, the G5-PB11 plasmid, a construct
that harbors a minimal simian virus 40 promoter with 6 Sp1
binding site and a TATA box, driving high basal activity, was
used to score for repression (29). Initially, we verified that the
proteins were correctly expressed upon transfection into
Saos-2 cells (Fig. 4A). As shown in Fig. 4B, the G5XN was
activated three- to fivefold by both the G4-63-11 and the G4-
63-12 fusion proteins. A construct in which both exons 11 and
12 were fused to GAL4 DNA-binding domain did not increase
transcription further (data not shown). The G4-63-13 and G4-
63-14 proteins had a slight inhibitory effect on the very low
level of transcription from this reporter. On the other hand,
when the latter were used with the G5-PB11 reporter plasmid,
which has high intrinsic activity, they repressed transcription
four- to fivefold (Fig. 4C). These data uncover two new func-
tions located at the C terminus of p63: (i) an activation do-
main, termed hereafter TA2, encoded within exons 11 and 12
that is most likely responsible for the transcriptional activation
observed with the N isoforms in transient reporter assays;
and (ii) a repressive domain, encoded by sequences within
exons 13 and 14.
Analysis of transcriptional activity of the EEC and AEC p63
mutants. The delineation of exon 13 sequences as a transcrip-
tional repressing part of p63 prompted us to examine the
activities of mutants causative of the human EEC and AEC
syndromes (8, 33). p63FS contains a mutation found in an
EEC syndrome patient containing an A insertion that gener-
ates a frameshift at amino acid 525 encoded within exon 13,
FIG. 2. Transactivation potential of p63 isoforms. (A) The trans-
fected proteins are correctly expressed. Saos-2 cells were transiently
transfected with 0.5 g of the indicated plasmids and lysed in 100 l of
lysis buffer 36 h after transfection. Different volumes of total cell
extracts were immunoblotted with anti-myc antibodies: p53 (10 l)
(lane 1), TAp63 (10 l) (lane 2), Np63 (10 l) (lane 3), TAp63
(25 l) (lane 4), Np63 (10 l) (lane 5), TAp63 (25 l) (lane 6),
and Np63 (10 l) (lane 7). (B) Saos-2 cells were transfected with
the p21/WAFCAT reporter plasmid (0.5 g) (open bar). Different
amounts of expression plasmids for p53 and p63 isoforms were co-
transfected (5, 25, 100, and 300 ng; dotted, black, dashed, and gray
bars, respectively). After 36 h, cells were harvested and CAT activity
was determined. (C) Saos-2 cells were transfected with the pBP100
reporter plasmid (0.5 g) (open bar) and with expression plasmids as
in panel B. (D) Saos-2 cells were transfected with the Hsp70 reporter
plasmid (0.25 g) (open bar) and with expression plasmids (100, 300,
and 500 ng; dashed, gray and squared bars, respectively). The basal
activity of the reporters was set to 1. Data are presented as fold
activation or repression relative to the sample without effector. Each
histogram bar represents the mean of three independent transfection
duplicates. Standard deviations are indicated.
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leading to a predicted premature stop; p63 AEC missense
mutants L518F, G534V, T537P, and Q540L are also encoded
within exon 13 in the 1 and 3 helices and L2 of the SAM
domain (33). Because of the alternative splicing at the C ter-
minus (Fig. 1), these mutations are present only in the 
isoforms. We performed the reporter assays outlined above
with expression vectors coding for these mutants in the TA and
N configurations. The TA and N p63FS mutants showed
similar behavior, activating the p21 and MDM2 promoters
(Fig. 5A and B): both were among the strongest activators,
unlike their wt counterparts, which were ineffective in MDM2
activation. With the AEC mutants, all the N isoforms were
unable to activate p21 or the MDM2 promoter, while the TA
isoforms were active on MDM2 but not on p21. The gain of
transcription function of TA540 is particularly striking, for it is
the strongest among the activators tested on MDM2. In re-
pression assays, the frameshift mutants showed no differences
with respect to the wt isoforms (Fig. 5C), whereas the TA AEC
mutants completely lost the capacity to repress Hsp70 tran-
scription. Indeed, all N AEC constructs, whose N wt coun-
terpart has no repression capacity, showed a robust activation
of this promoter. The mutants were checked for protein ex-
pression in immunoblot analysis with specific anti-myc tag an-
tibodies, and all were expressed at equivalent levels (Fig. 5D).
From this analysis, we conclude that single amino acid sub-
stitutions within the SAM domain turn an ineffective acti-
vator, such as TAp63, into a powerful one (Fig. 5B) and at
the same time render the proteins incapable of repression
(Fig. 5C). Furthermore, the transcriptional properties/behav-
ior of p63FS is clearly distinct from that of the AEC mutants.
To further clarify whether the AEC mutations alter the exon
13 repression domain identified above (Fig. 4C), we generated
constructs containing the AEC G534V and Q540L exon 13
mutants fused to the yeast GAL4 DNA-binding domain (G4-
13-534 and G4-13-540). The activities of the resulting con-
structs were assayed with the reporter used above (Fig. 4C).
The proteins were correctly expressed upon transfection into
Saos-2 cells (Fig. 5E). As shown in Fig. 5F, when assayed with
the G5-PB11 reporter, the repression capacities of G4-13-534
and G4-13-540 were modestly reduced compared to that of
G4-63-13. These data suggest that the AEC mutations do not
disrupt the exon 13 repression domain, but rather, in the entire
p63 protein, AEC mutations could prevent (i) the association
of a corepressor and/or (ii) interactions of the SAM domain
with the TA1 of p63.
Growth suppression by wt and mutant p63 isoforms. p53 is
known to inhibit growth and some of p63 isoforms have been
already checked for growth suppression in colony formationFIG. 3. The endogenous MDM2 mRNA is induced upon p63 trans-
fection. Northern analysis of total RNA extracted from Saos-2 cells
transiently transfected with the indicated plasmids is shown. MDM2
RNA was barely detectable in mock-transfected cells (lane 1). As
expected, p53 transfection induced MDM2 RNA expression (lane 2);
an even stronger induction was observed in the TA transfectants
(lane 5); transfection of the TA isoform resulted in a good induction
of MDM2 RNA (lane 7). Transfection of the TAp63, Np63, and
Np63 isoforms did not induce MDM2 RNA expression (lanes 3, 4,
and 6). The same filter was hybridized to a rat glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) cDNA probe for normalization of
RNA loading.
FIG. 4. Transcriptional activation and repression by Gal4-p63 ex-
ons. (A) Saos-2 cells were transiently transfected with 0.5 g of the
indicated plasmids and lysed in 100 l of lysis buffer 36 h after trans-
fection. Ten microliters of total cell extracts were immunoblotted with
anti-GAL4 antibodies. (B) G5XN reporter (0.5 g) (open bar) was
cotransfected into Saos-2 cells together with indicated GAL4 vectors
(black and dashed bars; 0.3 and 0.5 g, respectively). (C) PB11 re-
porter (0.5 g) (open bar) was cotransfected into Saos-2 cells together
with indicated GAL4 vectors (black and dashed bars; 0.3 and 0.5 g,
respectively). Data are presented as fold activation or repression rel-
ative to the sample without effector. Each histogram bar represents the
mean of three independent transfection duplicates. Standard devia-
tions are indicated.
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assays, known to reveal cell cycle blocking and proapoptosis
functions (37). We performed such experiments with Saos-2
cells stably transfected with the constructs used above, which
harbor a neomycin selection marker. The numbers of colonies
scored after 2 weeks of addition of G418 in the medium are
shown in Fig. 6A. As expected, p53 induced a dramatic de-
crease (50-fold) in colony numbers. In line with previous re-
ports, essentially the same picture was evident with all the
TAp63 isoforms. Among the mutants, TAp63FS and TA540
behaved like the wt p63 isoform, whereas TA518, TA534, and
to a lesser degree TA537 yielded five- to sevenfold more col-
onies than TAp63 yet clearly fewer than the pcDNA control.
As for the N isoforms, p63 and, more profoundly, p63
inhibited growth, whereas p63 and AEC mutants were essen-
tially negative in this assay: in fact, N518, N534, and N540
generated a consistently higher number of colonies. On the
other hand, p63FS behaved essentially like the p63 isoform,
being the strongest repressor of cell growth. Taken together,
these data highlight remarkable differences in terms of growth
suppression between (i) the TA and N isoforms, (ii) the /
and  isoforms, and (iii) the EEC and AEC mutants.
DISCUSSION
We have performed the first comprehensive and systematic
investigation of the transcriptional and growth inhibition ac-
tivities of the p63 isoforms identified so far: the results are
FIG. 5. Transcriptional regulation by EEC and AEC mutation.
(A) Saos-2 cells were transfected with the p21/WAFCAT reporter
plasmid (0.5 g) (open bar). Different amounts of expression plasmids
for p63 isoforms were cotransfected (5, 25, 100, and 300 ng; dotted,
black, dashed, and gray bars, respectively). After 36 h, cells were
harvested and CAT activity was determined. (B) Saos-2 cells were
transfected with the pBp100 reporter plasmid (0.5 g) (open bar) and
cotransfected as in panel A. (C) Saos-2 cells were transfected with the
Hsp70 reporter plasmid (0.25 g) (open bar) and cotransfected with
expression plasmids (5, 25, 100, 300 and ng; dotted, black, dashed, and
gray bars, respectively). (D and E) Saos-2 cells were transiently trans-
fected with 0.5 g of the indicated plasmids and lysed in 100 l of lysis
buffer 36 h after transfection. Twenty microliters of total cell extracts
were immunoblotted with anti-myc (D) and anti-GAL4 (E) antibodies.
(F) G5-PB11 reporter (0.5 g, open bar) was cotransfected into Saos-2
cells together with indicated GAL4 vectors (black and dashed bars, 0.3
and 0.5 g, respectively). Data are presented as fold activation or
repression relative to the sample without effector. Each histogram bar
represents the mean of three independent transfection duplicates.
Standard deviations are indicated.
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summarized in Table 1. We uncovered a novel activation do-
main, TA2, encoded within exons 11 and 12 and a repression
function encoded by exons 13 and 14. Most importantly, single
amino acid substitutions in the SAM domain completely abol-
ish inhibition function and, within the TA isoforms, acquire
activation potential. The biological importance of the SAM
domain was further detailed in colony assays using AEC mu-
tants. We conclude that the SAM domain is a dominant tran-
FIG. 6. Growth suppression by expression of wt and mutated p63 isoforms. (A) p53, p63 isoforms, and pcDNA expression vectors (0.3 g each)
were transfected into Saos-2 cells. After 2 weeks of selection, colonies were fixed and stained to demonstrate suppression of colony formation.
(B) The graph represents the number of colonies obtained with the indicated plasmids relative to that detected on the pcDNA transfected plates,
which was set to 1. The experiment was repeated three times in duplicate. Standard deviations are indicated.
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scriptional repression module crucial for the function of the 
isoform.
p63 TA2 activation domain. For all p53 family members, the
very N terminus of the protein harbors a transcriptional acti-
vation domain. Although far less conserved than the DNA-
binding subdomain, this highly acidic stretch shows some de-
gree of similarity among the three family members. The 
isoform in the N configuration has powerful activation po-
tential, suggesting that a second activation function was
present in p63. The analysis of N, lacking the SAM domain
and less active in transcription, suggested that sequences en-
coded by exons 11 and 12 are important for activation. That a
second activation domain, TA2, is positioned between amino
acids 410 and 512 is indeed documented by the GAL4 fusion
experiments (Fig. 4B). Several additional indications are in
keeping with the importance of TA2: (i) it is confined to dis-
crete exon-intron boundaries, as is often the case for function-
ally defined domains, and its genomic organization, differential
splicing, and primary amino acid sequence are conserved be-
tween p63 and p73. (ii) The analysis of the transcriptional
effects of p63 on natural promoters with TA and Np63
inducible cell lines showed that one of the p53 potential tar-
gets, GADD45, was activated exclusively by Np63, a result
well in line with the requirement of a second activation domain
(12). (iii) p73 was shown to contain an activation function
active in yeast and in mammalian cells between amino acids
380 and 499, a region that corresponds to p63 gene exons 11
and 12 (38, 45); moreover, one of the two p73 missense mu-
tations identified in human neuroblastomas involves a proline,
P425L, that is conserved in p63: the mutation indeed affects
activation function in GAL4 assays (43). (iv) This region has a
high proline content that is found in the activation domains of
many other transcription factors (25). Interestingly, the Blan-
dino and colleagues have recently shown that Yes-associated
protein, a WW domain adaptor, binds to a stretch of p73 that
is conserved within exon 12 of p63 and coactivates p73- and
p63-mediated transcription (42).
Finally, the residual activity of  isoforms observed in our
assays could well be due to 26 amino acids at the very N-
terminal end of the protein outside TA1 which are encoded by
additional splicing variants (3). A further activation function
was recently mapped to this region (12). In general, we provide
evidence that an endogenous gene is activated by the panel of
transfected p63 isoforms. It should be mentioned, however,
that we were unable to activate the endogenous MDM2 gene
by overexpressing Np63 in the absence of TA1, unlike the
robust activation observed with the TA versions. This result is
remindful of the p73 case, for which activation in reporter
assays by overexpression was not completely paralleled by
stimulation of endogenous gene expression (24). Several ex-
planations can be invoked to explain this behavior, since (i) the
reporter genes are not recapitulating the whole regulation and
(ii) the endogenous gene is constrained by chromatin struc-
tures.
The p63 SAM repression domain. The repressive activity
elicited by the SAM domain encoded by exon 13 was charac-
terized in more detail, revealing the following. (i) Removal of
this region by alternative splicing ( versus ) dramatically
increases the activation potential of p63 on MDM2. (ii) Fusion
of this domain to a GAL4 DNA-binding domain repressed an
SV40 promoter reporter construct. (iii) In repression assays
with the HSP70 promoter, the AEC mutants led to a complete
subversion of the repression behavior within the TA config-
uration, turning these mutants into activators, albeit weak
ones. Results obtained with p73 support this idea: a C-terminal
deletion to amino acid 427, including the SAM domain, has
been shown to yield a more active protein (43, 45). A clear
difference between the  and  isoforms within the TA con-
figuration was reported on the MDM2 and GADD45 promot-
ers but not on the p21 promoter (24). We also found that a
C-terminal deletion augmented activity.
The three-dimensional structure of the p73 SAM domain
between amino acids 491 to 550 has been recently solved by
nuclear magnetic resonance: it is composed of five -helices
that are structurally very similar to the prototype SAM domain
of the ephrin B2 receptor (9). Interestingly, the AEC muta-
tions studied here are clustered and are predicted to be either
modifying the overall structure and stability of the helices or
causing subtle differences in the solvent-accessible surface of
3 (33). The  isoforms, in addition to splicing of the SAM,
also are subject to a change in the frame and loss of the amino
acids encoded by exon 14. Interestingly, mutations causing
premature stop codons in exon 14 have been associated with
limb mammary syndrome and SHFM syndrome, pointing to a
relevant role of this exon (46).
What are the mechanisms by which the  isoforms inhibit
transcription? The interpretation must consider the fact that
the DNA-binding domain is intact and presumably capable of
targeting the protein to the various promoters. The SAM do-
main is thought to be a protein-protein interacting module that
mediates homo- and heterodimerization (44). Self-association
of p63 and binding to p73 are not elicited by the SAM domain
(10). Rather, it is tempting to speculate that a corepressor
protein is normally bound to this part of p63 isoforms, pos-
sibly interfering with DNA binding and rendering p63 tran-
scriptionally inactive: alternatively spliced  and  isoforms or
TABLE 1. Summary of the transcriptional and growth suppression
activities of wild-type and mutated p63a
Protein Activation Repression Growth suppr.
p53   
TAp63   
Np63 	 	 
TAp63   
Np63   
TAp63   
Np63   	
TAp63FS   
Np63FS   
TA518  		 
N518 	 		 		
TA534  		 
N534 	 		 		
TA537   
N537 	 		 	
TA540  	 
N540 	 		 		
a Data obtained concerning transcriptional activation, transcriptional repres-
sion, and growth suppression (suppr.) capacities of p63 are shown. The strength
of the response indicated by the  and 	 signs is relative to that obtained with
p53, which was set as  in all cases.
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mutations would prevent the association of such a corepressor
and hence unmask the activation domains.
AEC/EEC and p63 transcriptional control. Both AEC and
EEC syndromes are dominant traits caused by the dominant-
negative activities of the mutated p63 isoforms. The EEC sin-
gle amino acid mutations described so far concern the DNA-
binding subdomain of p63 and affect all isoforms (2, 8): many
correspond to residues in p53, such as R204, R279, R280, and
R304 in p63, which are the equivalents of p53 mutational hot
spots in innumerable human tumors (34, 41). Their effects on
artificial p53 reporters have been observed: they were unable
to activate when transfected alone and were unable to repress
cotransfected p53 or TAp63 (8, 33, 48). The equivalent p53
mutants are known to behave in very much the same way:
indeed, some of the p63 missense mutations in EEC syndrome,
such as R204 and R304, which are shared between EEC and
SHFM (46), behaved very much like the p53 equivalents in
transfections assays (8). Biochemical work indicated that het-
erotetramers between p63 and p73 with p53 are not easily
observed in vitro and in vivo (10). However, it was recently
found that p53 DNA-binding mutants are specifically capable
of heteromerizing with p63 and p73, hence lending support to
a model whereby the function of these two proteins would also
be influenced in a negative way (14).
A fundamentally different scenario is evident for the AEC
missense mutants. First, none of the mutations identified so far
involves the DNA-binding domain; second, unlike the mis-
sense EEC, they are present only in the  isoforms. These
mutants showed no differences in the activation of an artificial
reporter containing 13 p53 binding sites in front of a minimal
promoter, compared to the wt TAp63 counterpart (33): this
behavior is indeed confirmed in our study of the p21 promoter,
but it is clearly different from the pattern of activation ob-
served on MDM2, suggesting that AEC mutants affect only a
subset of p63 targets. The results obtained with AEC muta-
tions in the GAL4 context (Fig. 5F) suggest that rather than
disrupting the exon 13 repression domain, AEC mutations
prevent association with a corepressor necessary to induce the
down-modulation normally seen in the TAp63 protein. This
suggests that the role of the repression domain is dominant, a
notion that is consistent with the results obtained with exon
13-lacking  and  isoforms. It is even possible that the nega-
tive role of the SAM domain affects the TA1 activation func-
tion.
AEC patients have a peculiar phenotype of skin lesions, in
particular severe scalp dermatitis (46). Skin biopsies of AEC
and EEC syndrome patients documented p63 staining in the
differentiating cells of the suprabasal layer, where p63 is nor-
mally absent (33). The TA and N isoforms are known to be
differentially expressed in keratinocyte differentiation systems:
the former increases and the latter conversely decreases upon
loss of growth capacity and differentiation (11, 39). Growth
suppression assays used in our study are the results of both
activation of proapoptosis genes and repression of cell cycle
promoting genes. In general, the colony assays of the AEC TA
and N isoforms suggest a more complex picture that might
involve an altered capacity in activating growth-stimulating
genes and in repressing proapoptosis genes. The dramatic in-
crease in growth inhibition in the N and NFS isoforms
possibly indicates that proapoptosis genes are not repressed.
Conversely, the importance of TA2 is highlighted by the com-
parison between the N and  isoforms, in which it is evident
that loss of exons 11 and 12 leads to lack of activation of
proapoptosis genes. Thus, the severe skin phenotype of these
patients might be a complex combination of altered cell re-
newal and lack of expression of highly specific differentiation
genes. This interpretation requires the exact knowledge of p63
isoforms present in the basal layer in vivo, at present unknown,
and the identification of p63 endogenous targets, some of
which are emerging (11). Identification of bona fide p63 targets
in vivo is clearly mandatory in order to fully understand the
activation and repression functions of this transcription factor.
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